Blood Eosinophils to Direct Corticosteroid Treatment of Exacerbations of Chronic Obstructive Pulmonary Disease

Abstract

Rationale: Exacerbations of chronic obstructive pulmonary disease (COPD) and responses to treatment are heterogeneous. Objectives: Investigate the usefulness of blood eosinophils to direct corticosteroid therapy during exacerbations. Methods: Subjects with COPD exacerbations were entered into a randomized biomarker-directed double-blind corticosteroid versus standard therapy study. Subjects in the standard arm received prednisolone for 2 weeks, whereas in the biomarker-directed arm, prednisolone or matching placebo was given according to the blood eosinophil count biomarker. Both study groups received antibiotics. Blood eosinophils were measured in the biomarker-directed and standard therapy arms to define biomarker-positive and -negative exacerbations (blood eosinophil count . and < 2%, respectively). The primary outcome was to determine noninferiority in health status using the chronic respiratory questionnaire (CRQ) and in the proportion of exacerbations associated with a treatment failure between subjects allocated to the biomarker-directed and standard therapy arms. Measurements and Main Results: There were 86 and 80 exacerbations in the biomarker-directed and standard treatment groups, respectively. In the biomarker-directed group, 49% of the exacerbations were not treated with prednisolone. CRQ improvement after treatment in the standard and biomarker-directed therapy groups was similar (0.8 vs. 1.1; mean difference, 0.3; 95% confidence interval, 0.0-0.6; P ¼ 0.05). There was a greater improvement in CRQ in biomarker-negative exacerbations given placebo compared with those given prednisolone (mean difference, 0.45; 95% confidence interval, 0.01-0.90; P ¼ 0.04). In biomarker-negative exacerbations, treatment failures occurred in 15% given prednisolone and 2% of those given placebo (P ¼ 0.04). Conclusions: The peripheral blood eosinophil count is a promising biomarker to direct corticosteroid therapy during COPD exacerbations, but larger studies are required. Clinical trial registered with www.controlled-trials.com (ISRCTN 92422949).Keywords: chronic obstructive pulmonary disease; exacerbations; prednisolone; infection; eosinophils Acute exacerbations of chronic obstructive pulmonary disease (COPD) are associated with substantial morbidity and mortality (1, 2) and are heterogeneous with respect to inflammation (3, 4) and etiology (5-7). Although primarily associated with asthma, eosinophilic airway inflammation is present in some patients with COPD (8). Previous studies have shown that a sputum eosinophilia is associated with a positive response to corticosteroid treatment in stable COPD (9-11), and the sputum eosinophil count can be used to titrate corticosteroid therapy to reduce exacerbations of COPD (12).Current guidelines advocate the use of systemic corticosteroids during acute exacerbations of COPD because of improvements in the rate of recovery (13,14); this is despite being associated with significant side effects (15) and with limited benefits in reducing mortality (14). Increased eosinophilic air...

Lung microbiome dynamics in COPD exacerbations

“…Here, we performed a longitudinal 16S rRNA-based microbiome survey on 476 sputum samples collected from 87 subjects with COPD from BEAT-COPD (Biomarkers to Target Antibiotic and Systemic Corticosteroid Therapy in COPD Exacerbations) [12,13], which, to our knowledge, is the largest well-characterised COPD lung microbiome cohort to date. We found that changes in the lung microbiome were associated with specific clinical and biochemical characteristics of COPD, thereby providing further insights into the relationships among the lung microbial community, host inflammatory responses and disease pathogenesis.…”

Relationship between blood and bronchial submucosal eosinophilia and reticular basement membrane thickening in chronic obstructive pulmonary disease

“…Alternative simpler biomarkers of eosinophilic inflammation are required. The peripheral blood eosinophil count and percentage are associated with a sputum eosinophilia1, 4 and can be successfully used to direct corticosteroid therapy in COPD 5. However, to date, studies have not explored the relationship between peripheral blood eosinophil count and the degree of submucosal eosinophils and remodelling in COPD.…”

Phenotyping chronic obstructive pulmonary disease (COPD) exacerbations: realising personalised medicine

“…Bafadhel et al performed a double-blind RCT using peripheral blood eosinophil count as a biomarker to guide oral corticosteroid treatment in outpatients with acute exacerbations of COPD. 13 In this study, a safe reduction in inappropriate oral corticosteroid prescriptions was demonstrated. Intriguingly, patients without eosinophilia treated with systemic corticosteroids had more adverse events and a lower rate of recovery, which suggests that this biomarker identifies a group of patients who might benefit from and another group of patients harmed by corticosteroid therapy.…”